interim management statement - investor ab · material items affecting comparability - sarnova in...

26
1 Interim Management Statement January-September 2019 Johan Forssell, CEO

Upload: others

Post on 17-Jul-2020

1 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Interim Management Statement - Investor AB · Material items affecting comparability - Sarnova in Q3 2019, Mölnlycke in Q3 2018. 10 A provider of advanced products for treatment

1

Interim Management

StatementJanuary-September 2019

Johan Forssell, CEO

Page 2: Interim Management Statement - Investor AB · Material items affecting comparability - Sarnova in Q3 2019, Mölnlycke in Q3 2018. 10 A provider of advanced products for treatment

Q3 2019 highlights

2

EQT ABSuccessfully

listed on

NASDAQ

Stockholm

22%Adjusted EBITA

growth in major

subsidiaries

8% Adjusted NAV

growth and

TSR(SIXRX +2%)

ABB SEK 1.3bn

invested

4.6%Leverage,

strong cash

flow, financial

flexibility

Page 3: Interim Management Statement - Investor AB · Material items affecting comparability - Sarnova in Q3 2019, Mölnlycke in Q3 2018. 10 A provider of advanced products for treatment

3

Macro Outlook – prepared for different scenarios

Page 4: Interim Management Statement - Investor AB · Material items affecting comparability - Sarnova in Q3 2019, Mölnlycke in Q3 2018. 10 A provider of advanced products for treatment

Investments in EQT

4

Page 5: Interim Management Statement - Investor AB · Material items affecting comparability - Sarnova in Q3 2019, Mölnlycke in Q3 2018. 10 A provider of advanced products for treatment

• Long-term investment horizon in EQT

– 18.3 percent ownership in EQT AB following utilization of

over-allotment option in October

• SEK 37bn in total investments

– Of which SEK 21bn in fund investments

• SEK 2.1bn net cash flow to Investor, of which SEK 1.6bn related

to secondary sale of shares in conjunction with IPO

5

EQT AB successfully listed on NASDAQ Stockholm

Page 6: Interim Management Statement - Investor AB · Material items affecting comparability - Sarnova in Q3 2019, Mölnlycke in Q3 2018. 10 A provider of advanced products for treatment

Listed Companies

6

Page 7: Interim Management Statement - Investor AB · Material items affecting comparability - Sarnova in Q3 2019, Mölnlycke in Q3 2018. 10 A provider of advanced products for treatment

Listed Companies

7

Page 8: Interim Management Statement - Investor AB · Material items affecting comparability - Sarnova in Q3 2019, Mölnlycke in Q3 2018. 10 A provider of advanced products for treatment

Patricia Industries

8

Page 9: Interim Management Statement - Investor AB · Material items affecting comparability - Sarnova in Q3 2019, Mölnlycke in Q3 2018. 10 A provider of advanced products for treatment

Patricia Industries

Organic sales growth, % EBITA growth, % (as reported in companies’ local currencies)

9

Strong performance in Q3 2019

Braun

Ability

VecturaGrand

Group

Laborie MölnlyckePermobilSarnova Piab

73%

67%

39%

27%

20%17%

13%8%

Vectura Sarnova Mölnlycke Braun

Ability

Permobil Grand

Group

Piab Laborie

18%

-2%

8%

7%

3%

6%

3%

-1%

Material items affecting comparability - Sarnova in Q3 2019, Mölnlycke in Q3 2018

Page 10: Interim Management Statement - Investor AB · Material items affecting comparability - Sarnova in Q3 2019, Mölnlycke in Q3 2018. 10 A provider of advanced products for treatment

10

A provider of advanced products for treatment and prevention of wounds and single-use surgical solutions

Q3 2019

• Organic sales growth +7 percent in constant currency

• Wound Care +7 percent driven by product

launches and Emerging Markets

• Surgical +6 percent driven by Gloves and

Surgical Trays

• All geographies contributed to growth, Emerging

Markets at the highest rate

• EBITA margin higher compared to last year, which

was negatively impacted by a write-down

IFRS 16 implemented as of the first quarter 2019

0

5

10

15

20

25

30

35

0

50

100

150

200

250

300

350

400

450

Q316

Q416

Q117

Q217

Q317

Q417

Q118

Q218

Q318

Q418

Q119

Q219

Q319

%EUR m

Sales EBITDA, % EBITA, %

Page 11: Interim Management Statement - Investor AB · Material items affecting comparability - Sarnova in Q3 2019, Mölnlycke in Q3 2018. 10 A provider of advanced products for treatment

11

A provider of advanced mobility and seating rehab solutions

Q3 2019

• Organic sales growth +3 in constant currency

• All product segments contributed to growth. Strong

growth in APAC, Americas and EMEA stable

• EBITA margin improved driven by efficiency

improvements and favorable currency impact. Last

year also negatively impacted by CEO transition costs

and asset disposal

• TiLite MXA, new folding wheelchair for active use,

launchedIFRS 16 implemented as of the first quarter 2019

0

5

10

15

20

25

0

200

400

600

800

1 000

1 200

Q316

Q416

Q117

Q217

Q317

Q417

Q118

Q218

Q318

Q418

Q119

Q219

Q319

%SEK m

Sales EBITDA, % EBITA, %

Page 12: Interim Management Statement - Investor AB · Material items affecting comparability - Sarnova in Q3 2019, Mölnlycke in Q3 2018. 10 A provider of advanced products for treatment

12

A provider of innovative capital equipment and consumables for the diagnosis and treatment of urologic and

gastrointestinal disorders

Q3 2019

• Organic sales growth -2 percent in constant currency

• Profitability continued to improve driven by cost

savings materializing from Cogentix acquisition and

restructuring of the European business

• Commercial launch of the next generation NXT

urodynamics platform in September

IFRS 16 implemented as of the first quarter 2019

-15

-10

-5

0

5

10

15

20

25

30

35

40

0

10

20

30

40

50

60

Q316

Q416

Q117

Q217

Q317

Q417

Q118

Q218

Q318

Q418

Q119

Q219

Q319

%USD m

Sales EBITDA, % EBITA, %

Page 13: Interim Management Statement - Investor AB · Material items affecting comparability - Sarnova in Q3 2019, Mölnlycke in Q3 2018. 10 A provider of advanced products for treatment

13

A manufacturer of wheelchair accessible vehicles and wheelchair lifts

Q3 2019

• Organic sales growth +6 percent in constant currency

• Growth driven by Consumer WAVs

• EBITA margin improved, driven by operating

efficiency improvements and supply chain

optimization initiatives

IFRS 16 implemented as of the first quarter 2019

0

2

4

6

8

10

12

0

50

100

150

200

250

Q316

Q416

Q117

Q217

Q317

Q417

Q118

Q218

Q318

Q418

Q119

Q219

Q319

%USD m

Sales EBITDA, % EBITA, %

Page 14: Interim Management Statement - Investor AB · Material items affecting comparability - Sarnova in Q3 2019, Mölnlycke in Q3 2018. 10 A provider of advanced products for treatment

14

A provider of gripping and moving solutions for automated manufacturing and logistics processes

Q3 2019

• Organic sales growth -1 percent in constant currency

• Europe and APAC grew slightly, Americas declined.

Strong growth in Ergonomic Handling, Robotic

Gripping remained weak

• EBITA margin improved driven by good cost control,

favorable mix and the weak SEK

• Clas Gunneberg assumed the CEO position

IFRS 16 implemented as of the first quarter 2019

0

5

10

15

20

25

30

35

40

0

50

100

150

200

250

300

350

400

Q117

Q217

Q317

Q417

Q118

Q218

Q318

Q418

Q119

Q219

Q319

%SEK m

Sales EBITDA, % EBITA, %

Page 15: Interim Management Statement - Investor AB · Material items affecting comparability - Sarnova in Q3 2019, Mölnlycke in Q3 2018. 10 A provider of advanced products for treatment

15

A specialty distributor of healthcare products in the U.S.

Q3 2019

• Organic sales growth +8 percent in constant currency

• Mutual agreement to transition distribution of several

products from Sarnova to Ambu

• Excluding profit contribution from Ambu transition,

EBITA margin in line with last year

• Acquisition and integration of emergency medical

services business of Concordance Healthcare

Solutions completed

IFRS 16 implemented as of the first quarter 2019

0

2

4

6

8

10

12

14

16

18

0

20

40

60

80

100

120

140

160

180

Q117

Q217

Q317

Q417

Q118

Q218

Q318

Q418

Q119

Q219

Q319

%USD m

Sales EBITDA, % EBITA, %

EBITDA adjusted, % EBITA adjusted, %

Page 16: Interim Management Statement - Investor AB · Material items affecting comparability - Sarnova in Q3 2019, Mölnlycke in Q3 2018. 10 A provider of advanced products for treatment

16

A provider of mobile voice and broadband services in Sweden and Denmark

Q3 2019

• Subscription base +31,000

• Service revenue +4 percent excluding previously

communicated Swedish VAT ruling

• Excl. IFRS 16 and Swedish VAT ruling, EBITDA

+10 percent

• In October, Three improved its customer satisfaction

to highest level ever in annual SKI customer

satisfaction survey

IFRS 16 implemented as of the first quarter 2019

*EBITDA excluding charges related to VAT rulings and IFRS 15 impact

-30

-20

-10

0

10

20

30

40

50

0

500

1 000

1 500

2 000

2 500

3 000

3 500

Q316

Q416

Q117

Q217

Q317

Q417

Q118

Q218

Q318

Q418

Q119

Q219

Q319

%SEK m

Sales EBITDA reported, % EBITDA adjusted*, %

Page 17: Interim Management Statement - Investor AB · Material items affecting comparability - Sarnova in Q3 2019, Mölnlycke in Q3 2018. 10 A provider of advanced products for treatment

17

Average annual total shareholder return

0

5

10

15

20

25

30

35

YTD 1 year 5 years 10 years 20 years

Percent

Investor B SIXRX Return requirement

As of September 30, 2019

Page 18: Interim Management Statement - Investor AB · Material items affecting comparability - Sarnova in Q3 2019, Mölnlycke in Q3 2018. 10 A provider of advanced products for treatment

Interim Management

StatementJanuary-September 2019

Helena Saxon, CFO18

Page 19: Interim Management Statement - Investor AB · Material items affecting comparability - Sarnova in Q3 2019, Mölnlycke in Q3 2018. 10 A provider of advanced products for treatment

10-year Net Asset Value development

19

0

50

100

150

200

250

300

350

400

450

500

12

SEK bn

09 10 11 14 1813 15 16 17 19

388

456

Reported NAV

Adjusted NAV

Page 20: Interim Management Statement - Investor AB · Material items affecting comparability - Sarnova in Q3 2019, Mölnlycke in Q3 2018. 10 A provider of advanced products for treatment

Listed Companies

20

Q3 2019 Summary

6 113

2 217 2 0791 786 1 674

1 359

-162

-836-1 128

-2 198 -2 355-2 860

-3 000

-2 000

-1 000

0

1 000

2 000

3 000

4 000

5 000

6 000

7 000

ELUXATCONasdaqAZN SEB Epiroc ABB Saab HUSQ Ericsson Wärtsilä Sobi

TSR 15 6 10 4 10 2 -1 -7 -13 -10 -17 -15

SEK 310bn

• Total contribution to NAV SEK 6bn

• Listed Companies TSR 2%, in line with SIXRX

Atlas Copco20%

ABB 15%

AstraZeneca14%

SEB 13%

Epiroc 7%

Nasdaq 6%

Ericsson 6%

Sobi 5%

Electrolux 4%

Saab 4%

Wärtsilä 4% Husqvarna 2%

SEK

316bn

Page 21: Interim Management Statement - Investor AB · Material items affecting comparability - Sarnova in Q3 2019, Mölnlycke in Q3 2018. 10 A provider of advanced products for treatment

Patricia Industries

21

Q3 2019 Summary

8 491

1 820

1 6571 387

7781 775

Total NAV

June 30,

2019

Mölnlycke Total NAV

Sept 30,

2019

Financial

Investments

VecturaGrand GroupBraunAbility Three

Scandinavia

LaboriePermobil

125 506

-17 -184-899

140 313

Patricia

Cash

Estimated market value change

+13%value

increase

excl. cash

Page 22: Interim Management Statement - Investor AB · Material items affecting comparability - Sarnova in Q3 2019, Mölnlycke in Q3 2018. 10 A provider of advanced products for treatment

Major Drivers of Estimated Market Values Q3 2019

22

SEK +8.5bnHigher multiples, higher profit, cash flow and currency

impacted positively

Company

Est. market value

change Q3 2019 vs.

Q2 2019

Major drivers

SEK +1.4bnHigher profit, cash flow and currency impacted

positively

SEK +1.7bnHigher profit, higher multiples and currency impacted

positively

SEK +0.8bn Higher profit and cash flow impacted positively

SEK +1.8bn Higher profit and higher multiples

Page 23: Interim Management Statement - Investor AB · Material items affecting comparability - Sarnova in Q3 2019, Mölnlycke in Q3 2018. 10 A provider of advanced products for treatment

Financial Investments

23

Q3 2019 Summary

• Strategic priority to maximize value and redeploy proceeds

from Financial Investments

• Cash proceeds received from exits of WhiteHat Security,

Memira and NS Focus

• Receivable of SEK 791m related to the sale of NS Focus

outstanding as of September 2019

• After the end of the quarter, the holding in HireVue was fully

exited

Five largest financial investments, Sept 30, 2019

Company Region Business Listed/

unlisted

Reported

value,

SEK m

Madrague Europe Hedge fund Unlisted 751

CDP Holding Asia IT Unlisted 548

HireVue U.S. IT Unlisted 442

Acquia U.S. IT Unlisted 394

CallFire U.S. IT Unlisted 372

Total 2 507

Page 24: Interim Management Statement - Investor AB · Material items affecting comparability - Sarnova in Q3 2019, Mölnlycke in Q3 2018. 10 A provider of advanced products for treatment

Financial Position as of September 30, 2019

24

• Leverage 4.6% (6.1% Dec 31, 2018)

• Net debt SEK 18.7bn

• Gross cash SEK 19.0bn

• Average maturity of the debt portfolio 11.3 years

Current rating

Standard & Poor’s AA-

Moody’s Aa3

0

5

10

15

Q115

Q215

Q315

Q415

Q116

Q216

Q316

Q416

Q117

Q217

Q317

Q417

Q118

Q218

Q318

Q418

Q119

Q219

Q319

Percent

Target range Leverage

Page 25: Interim Management Statement - Investor AB · Material items affecting comparability - Sarnova in Q3 2019, Mölnlycke in Q3 2018. 10 A provider of advanced products for treatment

We create value

for people and society

by building

strong and sustainable

businesses

Page 26: Interim Management Statement - Investor AB · Material items affecting comparability - Sarnova in Q3 2019, Mölnlycke in Q3 2018. 10 A provider of advanced products for treatment

Financial Calendar & Contact Details

26

Event Date

Year-End Report 2019 January 22, 2020

Interim Management Statement January – March 2020 April 22, 2020

Interim Report January – June 2020 July 17, 2020

Interim Management Statement January-September 2019 October 19, 2020

Contact Details

Viveka Hirdman-Ryrberg +46 70 550 3500

Head of Corporate Communication and Sustainability [email protected]

Magnus Dalhammar +46 73 524 2130

Head of Investor Relations [email protected]